摘要 : Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irAEs),significa... 展开
作者 | An-Jie Guo Qing-Yuan Deng Pan Dong Lian Zhou Lei Shi |
---|---|
作者单位 | |
期刊名称 | 《World Journal of Clinical Oncology 》 |
期刊英文名称 | 《世界临床肿瘤学杂志(英文)》 |
页码/总页数 | P.1002-1020 / 19 |
语种/中图分类号 | 汉语 / R730.3 |
关键词 | Immunotherapy Immune checkpoint inhibitors Immune-related adverse events Biomarkers Cancers |
DOI | 10.5306/wjco.v15.i8.1002 |
基金项目 | Supported by The Fundamental Research Funds for the Central Universities,No.2019CDYGYB024;The National Natural Science Foundation of China,No.31300726;The Chongqing Primary and Middle School Innovation Talent Training Project,No.CY220113. |